Added to YB: 2026-10-08
Pitch date: 2026-10-04
ARTV [bullish]
Artiva Biotherapeutics, Inc.
-10.22%
current return
Author Info
No bio for this author
Company Info
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers.
Market Cap
$348.6M
Pitch Price
$6.75
Price Target
N/A
Dividend
N/A
EV/EBITDA
-0.10
P/E
-2.22
EV/Sales
N/A
Sector
Biotechnology
Category
special_situation
Free under $10 Ticker Biotech Quarter Review Tier 1 basket — strategic biotech and specialty pharma - Artiva Biotherapeutics, Inc.
ARTV (quick overview): Artiva’s off-the-shelf, allogeneic NK-cell approach to autoimmune disease could be materially more practical than autologous CAR-T if immune-reset biology proves durable and autologous CAR-T is hard to scale. A major immunology company could partner, license or acquire the platform if clinical data prove durable, safe and operationally deployable; manufacturing convenience has no value without clinical differentiation, and efficacy, safety, persistence and consistency must hold up.
Read full article (1 min)